日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study

厄达替尼或厄达替尼联合西曲利单抗治疗伴有FGFR改变的转移性尿路上皮癌患者:II期NORSE研究的最终结果

Loriot, Yohann; Powles, Thomas; Moreno, Victor; Kang, Taek Won; Cicin, Irfan; Girvin, Angela; Akapame, Sydney; O'Hagan, Anne; Zhu, Wei; Tammaro, Meggan; Thomas, Shibu; Triantos, Spyros; Siefker-Radtke, Arlene O

Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations

饱和诱变法可鉴定出激活和诱导耐药性的FGFR激酶结构域突变

Tangermann, Carla; Ghosh, Avantika; Ziegler, Martin; Facchinetti, Francesco; Stappenbeck, Jannis; Carus Sahin, Yagmur Oyku; Riester, Marisa; Viardot, Luise Carmina; Zundel, Tobias; Friboulet, Luc; Hollebecque, Antoine; Naveja, José J; Wanninger, Angela; Hess, Maria Elena; Brummer, Tilman; Boerries, Melanie; Loges, Sonja; Loriot, Yohann; Illert, Anna L; Diederichs, Sven

Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma

Erdafitinib治疗FGFR改变的晚期或转移性胆管癌患者

Pant, Shubham; Park, Joon Oh; Su, Wu-Chou; Loriot, Yohann; Carranza, Omar; Corassa, Marcelo; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Prenen, Hans; Folprecht, Gunnar; Winter, Helen; Dal Molin, Graziela Z; Shen, Lin; Qian, Jiaqi; Liao, Huimin; Thomas, Shibu; Sweiti, Hussein; Triantos, Spyros; Feng, Yin-Hsun

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

对利拉夫格拉替尼的复发性耐药突变可指导 FGFR2 驱动肿瘤的治疗顺序。

Facchinetti Francesco, Hollebecque Antoine, Barbé Rémy, Jang Dong Man, Alonso-De-Castro Beatriz, Brayé Floriane, Bigot Ludovic, Nobre Catline, Da Silva Alice, Méteau Mélissandre, Delavigne Mathis, Soares Miguel, Italiano Antoine, Rodriguez Julieta, Mosele Fernanda, Beshiri Kristi, Ducreux Michel, Boilève Alice, Nikolaev Sergey, Alonso-Garcia Inmaculada, Vasseur Damien, Smolenschi Cristina, Bourien Héloise, Cotteret Sophie, Samaniego Juliette, Bernard Elsa, Nicotra Claudio, Ngo-Camus Maud, Nakazawa Seshiru, Tselikas Lambros, Badoual Cécile, André Fabrice, Eck Michael J, Olaussen Ken A, Loriot Yohann, Friboulet Luc

Telomere Dysfunction and Proteostasis Decline Define Distinct Pathways of Cellular Senescence in the Human Respiratory Tract

端粒功能障碍和蛋白质稳态下降定义了人类呼吸道细胞衰老的不同途径

Coquette, Céline; Bouchoucha, Kamar; Mahieu, Manon; Verleden, Stijn E; Loriot, Axelle; Norris, Kevin; Baird, Duncan M; Derumier, Amélie; Hoton, Delphine; De Sadeleer, Laurens; Vanstapel, Arno; Vanaudenaerde, Bart M; Goyet, Maëlle de Ville de; Brichard, Bénédicte; Froidure, Antoine; Wuyts, Wim; Van Slambrouck, Jan; Ceulemans, Laurens J; Trigaux, William; Huart, Caroline; Decottignies, Anabelle

Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity

Dabogratinib (TYRA-300),一种FGFR3亚型选择性抑制剂:抗肿瘤活性的临床前和初步临床证据

Starrett, Jacqueline H; Allen, Eric L; Neal, Melissa; Iyer, Samhita; Ye, Qing; Hudkins, Robert L; Degaonkar, Viraj; Lihou, Christine; Swanson, Ronald V; Boni, Valentina; Fuentes-Antrás, Jesús; Pobel, Cedric; Loriot, Yohann; Zalutskaya, Alena; Goluboff, Erik

How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 study

与铂类化疗相比,恩福妥单抗联合帕博利珠单抗治疗对晚期尿路上皮癌患者生活质量的影响:EV-302 研究患者报告结局的简明语言总结

Gupta, Shilpa; Loriot, Yohann; Van der Heijden, Michiel S; Bedke, Jens; Valderrama, Begoña P; Kikuchi, Eiji; Fléchon, Aude; Petrylak, Daniel; De Santis, Maria; Galsky, Matthew D; Lee, Jae Lyun; Swami, Umang; Sridhar, Srikala S; De Giorgi, Ugo; Wright, Phoebe; Shih, Vanessa; Lu, Yi-Tsung; Guan, Xuesong; Dillon, Ryan; Shetty, Aditya; Homet Moreno, Blanca; Beaumont, Jennifer L; Purnajo, Intan; McManus, Shauna; Powles, Thomas

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

下一代保留膀胱围手术期治疗肌层浸润性膀胱癌患者的试验终点

Necchi, Andrea; Galsky, Matthew D; Dizman, Nazli; Aggen, David H; Agarwal, Neeraj; Al-Ahmadie, Hikmat; Apolo, Andrea B; Ballas, Leslie; Bangs, Rick; Black, Peter C; Brausi, Maurizio; Brembilla, Giorgio; Cheng, Liang; Chiti, Arturo; Cimadamore, Alessia; Colecchia, Maurizio; Daneshmand, Siamak; Di Stasi, Savino; Efstathiou, Jason A; Filicevas, Alex; Geynisman, Daniel M; Grivas, Petros; Gupta, Shilpa; Iasonos, Alexia; James, Nick D; Lerner, Seth P; Loriot, Yohann; Makaroff, Lydia E; Maluf, Fernando; Moschini, Marco; Ostrovnaya, Irina; Pal, Sumanta K; Plimack, Elizabeth R; Prakash, Gagan; Psutka, Sarah P; Rosenberg, Jonathan E; Sadeghi, Sarmad; Schmidt, Bogdana; Schwartz, Lawrence H; Sonpavde, Guru P; St Laurent, Marie-Pier; Ye, Dingwei; Spiess, Philippe E; Kamat, Ashish M

COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts

COSMIC-021 Ib期研究:卡博替尼联合阿特珠单抗治疗局部晚期或转移性尿路上皮癌队列的结果

Pal, Sumanta K; Loriot, Yohann; Necchi, Andrea; Singh, Parminder; Castellano, Daniel; Pagliaro, Lance; Suarez, Cristina; McGregor, Bradley A; Vaishampayan, Ulka N; Hauke, Ralph J; Powles, Thomas; Van Herpen, Carla M L; Courtney, Kevin D; Dreicer, Robert; Sudhagoni, Ramu; Schwickart, Martin; Andrianova, Svetlana; Agarwal, Neeraj

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers

自分泌干扰素中毒介导 BRCA1/2 突变癌症中 ADAR1 依赖性合成致死

Roman M Chabanon ,Liudmila Shcherbakova ,Magali Lacroix-Triki ,Marine Aglave ,Jean Zeghondy ,Victor Kriaa ,Antoine Gougé ,Marlène Garrido ,Elodie Edmond ,Ludovic Bigot ,Dragomir B Krastev ,Rachel Brough ,Stephen J Pettitt ,Thibault Thomas-Bonafos ,Robert Samstein ,Christophe Massard ,Marc Deloger ,Andrew Nj Tutt ,Fabrice Barlesi ,Yohann Loriot ,Suzette Delaloge ,Marcel Tawk ,Cindy Degerny ,Yea-Lih Lin ,Barbara Pistilli ,Philippe Pasero ,Christopher J Lord ,Sophie Postel-Vinay